Accueil du site
Projets de développement
ONG/NGO Coopération décentralisée
Tanzanie
CONSOLIDATION OF A DEMONSTRATION FARM FOR VALIDATION OF ENTHNOMEDICAL AND ETHNOVETERINARY INFORMATION PERTAINED TO ENDANGERED PLANTS
Titre : CONSOLIDATION OF A DEMONSTRATION FARM FOR VALIDATION OF ENTHNOMEDICAL AND ETHNOVETERINARY INFORMATION PERTAINED TO ENDANGERED PLANTS
Pays : Tanzanie
Numéro projet : TAN/SGP/OP6/Y2/STAR/BD/2017/39
Domaine : Biodiversity
Durée : 7/2017 — 12/2018
Bénéficiaire :
Présentation
Project’s Objective : To consolidate a demonstration farm for valuation of ethnomedical and ethnoveterinary information pertaining to endangered medical plants.
Implementation Strategies : 1. Identify new plant species in Serengeti for including in the research garden 2. Expand the garden by constructing two zones 3. Conduct validation workshop for ethnomedical and ethnoveterinary information 4. Sensitize the general public to visit the botanical garden and appreciate the value of medicinal plants for socio-economic development.
Project Sustainability Strategies : • Attachment to the University will sustain operations of the garden • Importance of the medicinal plants for the management of human and livestock diseases will increase their demand • Water as a critical ingredient for the garden is guaranteed.
Anticipated project results : • Environmental benefits : (1) Medicinal plants that are on the verge of extinction will be conserved and saved from disappearance (2) The eco park to be developed will serve as a reservoir for plants which have significant importance to the society • Scientific benefits : Inclusion of medicinal plants from Serengeti ecosystem will increase the visibility of medicinal and nutraceutical potential of plants and herbs grown in the research garden. • Human Benefits : Enhanced drug research and discovery will give local communities with the capacity to access indigenous drugs that are effective for local strains of diseases.
Financement
Grant Amount (GEF) : US$ 46,913.00
Co-Finanshing Cash : US$ 69,867.00
Co-Finanshing in-Kind : US$ 11,678.00
Page publiée le 9 septembre 2018